Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – HIPAA
RWE 101 - HIPAA HIPAA (Health Insurance Portability and Accountability Act), enacted in 1996, is a federal law in the United States that establishes regulations for the protection of [...]
Real World Evidence (RWE) 101 – The Common Rule
RWE 101 - The Common Rule The Common Rule plays a significant role in the governance of observational studies. The Common Rule refers to a set of regulations and [...]
Real World Evidence (RWE) 101 – The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule)
RWE 101 - The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) The Tuskegee Syphilis Study, conducted from 1932 to 1972, stands as [...]
Real World Evidence (RWE) 101 – Observational Study vs Non-Interventional Study
RWE 101 - Observational Study vs Non-Interventional Study In the context of real-world evidence (RWE), the terms "observational study" and "non-interventional study" are often used interchangeably to refer to [...]
Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?
RWE 101 - Are Non-Interventional Studies Regulated? Yes, non-interventional studies (NIS) are regulated. While the specific regulations and requirements may vary by country, there are generally guidelines and provisions [...]
Real World Evidence (RWE) 101 – Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS)
RWE 101 - Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) In the context of real-world evidence (RWE) and regulatory frameworks, postmarket requirements (PMRs) and post-authorization safety studies (PASS) [...]







